ClinicalTrials.gg
Not yet recruitingNCT07471698Updated Mar 13, 2026

hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease

A Phase 1/2 interventional study of HiCM-188 Chitosan Patch and Blank Chitosan Patch in Ischemic Heart Failure and CABG-patients, sponsored by HELP Therapeutics Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by HELP Therapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 375 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
231st of 246
16 · median 127
Started
2026
with 41 others
Phase 1/2
14 of 375
7 open now
Primary completion
2028-10
later than 149 of 181 live
Registered
336th of 375
by date

Among the 375 studies in Heart Failure with a site in China, this one is the 231st largest by planned enrollment of the 246 interventional ones that give a count, is one of 42 that started in 2026, is one of 14 in phase 1/2, reaches primary completion later than 149 of the 181 other live ones, and was the 336th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 375 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

This is an exploratory study. A total of 16 patients meeting the inclusion and exclusion criteria and awaiting coronary artery bypass grafting (CABG) surgery will be enrolled. After providing informed consent, participants will be randomized 1:1 under double-blind conditions into two groups:

  1. CABG + HiCM-188-loaded chitosan patch group (patch size: 2×4 cm; containing 5 million cells per patch)
  2. CABG + blank chitosan patch group (identical in appearance but without HiCM-188 cells).

During CABG surgery, investigators will apply two HiCM-188-loaded chitosan patches onto the epicardial surface over regions of hypokinetic myocardium. The total transplanted cell dose per patient in the treatment group is 1 × 10⁷ . In the control group, eight patients will undergo identical surgical procedures with application of chitosan patches without HiCM-188 cells.

03

Conditions studied

  • Ischemic Heart Failure
  • CABG-patients

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 80 years (inclusive).
  2. Willingness and ability to give written .
  3. Chronic left ventricular dysfunction classified as Stage D ( end-stage heart failure) according to ACC staging criteria.
  4. functional class III-IV despite optimized guideline-directed medical therapy for heart failure.
  5. Indication for coronary artery bypass grafting (CABG), meeting one of the following anatomical criteria:

    5.1 Class I Indications :

    1. Left ventricular dysfunction with significant left main coronary artery disease;
    2. Left ventricular dysfunction with "left main equivalent" disease (i.e., ≥70% stenosis in proximal LAD or proximal LCx);
    3. Left ventricular dysfunction with two- or three-vessel disease including proximal LAD stenosis.

    5.2 Class IIa Indication : Left ventricular dysfunction with substantial viable, akinetic but revascularizable myocardium, not covered by above Class I anatomical criteria.

  6. (LVEF) ≤40% as measured by echocardiography or cardiac MRI within 6 months prior to enrollment (excluding measurements obtained within 1 month post-myocardial infarction).
  7. Echocardiographic evidence of regional wall motion abnormalities (hypokinesis, akinesis, or presence of ventricular aneurysm).

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the following criteria are ineligible for study participation:

  1. History of permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device implantation.
  2. Severe valvular heart disease or prior prosthetic valve replacement.
  3. Prior percutaneous coronary intervention (PCI) with stent implantation.
  4. Chronic atrial fibrillation.
  5. History of sustained ventricular tachycardia or aborted sudden cardiac death.
  6. Baseline estimated (eGFR) \<30 mL/min/1.73m².
  7. Hematocrit \<25%.
  8. Severe contrast media allergy (anaphylactic or life-threatening reaction history).
  9. Coagulation disorder ( >1.5 without therapeutic anticoagulation, \<50×10⁹/L, or bleeding diathesis).
  10. Known to penicillin or streptomycin.
  11. to undergoing cardiac MRI (e.g., incompatible implanted devices, severe claustrophobia unresponsive to premedication).
  12. History of solid organ or bone marrow transplantation.
  13. Active or history of cancer within the past 5 years (except non-melanoma skin cancer or carcinoma in situ).
  14. \<1 year due to non-cardiac conditions.
  15. Long-term systemic therapy (e.g., , TNF-α inhibitors).
  16. Contraindications to immunosuppressive therapy (e.g., active infection, uncontrolled diabetes, peptic ulcer disease).
  17. Active infectious diseases: , virus (HBV), virus (HCV), or syphilis (Treponema pallidum, TP).
  18. Currently participating in another interventional clinical trial.
  19. Pregnant or lactating women.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (estimated)

Study arms

  • Placebo comparator
    Control

    Drug: Blank Chitosan Patch

  • Experimental
    Treatment

    Drug: HiCM-188 Chitosan Patch

Interventions

  • Patients receive standard coronary artery bypass grafting (CABG) surgery plus epicardial application of two chitosan patches (each 2×4 cm in size, loaded with 5 million HiCM-188 cells), delivering a total dose of 1 × 10⁷ cardiomyocytes.

  • DrugBlank Chitosan Patch

    Patients receive standard CABG surgery plus epicardial application of two identical-appearing chitosan patches containing no HiCM-188 cells

06

What researchers measure

Primary outcomes

  1. Proportion and frequency of patients experiencing sustained ventricular tachycardia lasting more than 30 seconds

    Time frame: 1~6 Month Post-operation

  2. Incidence of allogeneic human-derived tumor formation

    CT scan of the abdomen and pelvis

    Time frame: Baseline, 1, 3, 6 months post-operation

Secondary outcomes

  1. Change in infarct size

    Assessed by MRI

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  2. Change in regional left ventricular function

    Assessed by MRI

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  3. Change in regional left ventricular wall thickness

    Assessed by MRI

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  4. Change in left ventricular end-diastolic wall thickness

    Assessed by both MRI and echocardiography

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  5. Change in left ventricular ejection fraction (LVEF)

    Assessed by both MRI and echocardiography

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  6. Change in left ventricular end-diastolic volume (LVEDV)

    Assessed by both MRI and echocardiography

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  7. Change in left ventricular end-systolic volume (LVESV)

    Assessed by both MRI and echocardiography

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  8. Change in regional myocardial perfusion

    Assessed by MRI

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  9. Six-minute walk test

    The distance a participant can walk on a flat, hard surface in 6 minutes

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  10. New York Heart Association (NYHA) functional classification

    A clinician-assessed 4-class scale (I-IV) evaluating symptom severity and functional limitation due to heart failure. Higher classes indicate greater impairment in physical activity tolerance.

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

  11. Minnesota Living with Heart Failure Questionnaire (MLHFQ) score

    A 21-item patient-reported outcome measure assessing health-related quality of life specific to heart failure. Total score ranges from 0 (no impact) to 105 (severe impact). Lower scores reflect better quality of life.

    Time frame: Baseline, 1, 3, 6, and 12 months post-operation

07

Study locations

1 site
  • The Second Xiangya Hospital of Central South University
    Changsha, China
    • Xiaobo Liao, MD, PhD · Principal investigator
    • Chengming Fan, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 43 phase 1/2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 13, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Oct 20, 2028
CompletionEst.
Oct 20, 2028
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07471698
Lead sponsor
HELP Therapeutics Co., Ltd.
Collaborators
Second Xiangya Hospital of Central South University
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Oct 20, 2028 (estimated)
Completion
Oct 20, 2028 (estimated)
Last update
Mar 13, 2026

Study contacts

Jiaxian Wang, MD, PhD
Contact
wangjx@helpsci.com.cn
+86-18565616060

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HICM-188

Start the discussion